Tag: "remicade" at biology news

Remicade data in ankylosing spondylitis show improvement in spinal mobility and spinal inflammation

BARCELONA, Spain, 15 June 2007 Data presented today at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology showed that patients with ankylosing spondylitis (AS) who received REMICADE (infliximab) over two years experienced significant improvement in spinal mobility. In addition, REMICADE-treated patients showed sustained reductions in spinal inflammation thr...

Long-term ulcerative colitis study shows Remicade responders maintained improvement

... The ACT extension trials were conducted in both the United States and Europe, under co-principle investigators William Sandborn, M.D. of the Mayo Clinic and Walter Reinisch, M.D., of the Un...

New analyses reinforce efficacy of Remicade in treatment of severe psoriasis

WASHINGTON, DC, February 2, 2007 -- Findings from an integrated analysis of data from three pivotal, randomized, placebo-controlled trials showed that at week 10 more than three-quarters of patients with severe psoriasis receiving REMICADE (infliximab) 3 mg/kg or 5 mg/kg achieved a 75 percent improvement in the chronic, inflammatory skin disease as measured by the Psoriasis Area Severity Index (...

Remicade therapy shown to improve productivity in patients treated for chronic plaque psoriasis

WASHINGTON, D.C., February 2, 2007 -- Investigators reported today at the American Academy of Dermatology annual meeting that patients with moderate to severe plaque psoriasis receiving REMICADE (infliximab) induction and maintenance therapy experienced significant improvements in productivity at week 10, which were sustained through week 50. After 10 weeks, patients receiving REMICADE 3 mg/kg...

Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half

LAS VEGAS, Nev., October 23, 2006 -- Patients with ulcerative colitis (UC) treated with REMICADE (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year compared with placebo, according to an analysis of long-term data from a Phase 3 clinical trial (Active Ulcerative Colitis Trial 1, ACT 1) presented at the American College of Gastroenterology (ACG) meeti...

REMICADE Phase 3 data show rapid, significant, long-term psoriasis improvement

Phase 3 data show treatment with REMICADE (infliximab) resulted in rapid, significant improvement and long-term response in patients with moderate to severe plaque psoriasis. Findings from the EXPRESS II trial, a placebo-controlled, dose-ranging study of REMICADE 3 mg/kg and 5 mg/kg, showed that every eight week maintenance therapy resulted in greater long-term skin clearance compared with "as-n...

Data in New England Journal of Medicine show benefits of REMICADE in ulcerative colitis patients

HORSHAM, Pa., and KENILWORTH, N.J., December 8, 2005 Landmark studies published today in The New England Journal of Medicine demonstrate the benefits of treatment with REMICADE (infliximab) in patients with ulcerative colitis (UC). ...... At week 8, in both the 54-week ACT 1 trial and the 30-week ACT 2 trial, statistically significant differences in the proportion of patients in clinical respon...

Active psoriatic arthritis patients on REMICADE achieve major clinical response in arthritis

SAN DIEGO, CALIF., NOVEMBER 13, 2005 New data, including two-year treatment duration, show a significantly higher proportion of patients with active psoriatic arthritis receiving REMICADE (infliximab) achieved and sustained a high degree of clinical improvement in arthritis, as assessed using the rheumatoid arthritis (RA) definition for "major clinical response," compared with patients receiving...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a ... announced that its DigitalPersona ® Pro Enterprise ... have been deployed throughout First Bank branch locations ... South Carolina and Virginia. First Bank, ... Southern Pines, North Carolina , selected ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
(Date:11/18/2014)... WASHINGTON , Nov. 18, 2014  The ... Security Industry Association today jointly announce the formation ... and release of its Identity and Biometric ... (Framework). The Framework received official support from BORDERPOL, ... governments to improve and provide expertise regarding border ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
Other Tags
exposedinstitutionalmulticurryfailingpretaterraconceptshardeningrolipramreversedfeetcriminalteaspoonsdisappearingwon